| 王登灿,陈焰烽,郑 炜,贾晓鑫,周德奇.加味八珍汤联合mFOLFOX6方案对晚期结直肠癌患者肿瘤标志物、免疫功能和外周血PI3K-Akt信号通路的影响[J].现代生物医学进展英文版,2023,(4):666-670. |
| 加味八珍汤联合mFOLFOX6方案对晚期结直肠癌患者肿瘤标志物、免疫功能和外周血PI3K-Akt信号通路的影响 |
| Effects of Jiawei Bazhen Decoction Combined with mFOLFOX6 Regimen on Tumor Markers, Immune Function and Peripheral Blood PI3K-Akt Signal Pathway in Patients with Advanced Colorectal Cancer |
| Received:July 18, 2022 Revised:August 15, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.04.013 |
| 中文关键词: 八珍汤 mFOLFOX6方案 晚期 结直肠癌 肿瘤标志物 免疫功能 PI3K-Akt信号通路 |
| 英文关键词: Jiawei Bazhen decoction mFOLFOX6 regimen Advanced Colorectal cancer Tumor markers Immune function PI3K-Akt signal pathway |
| 基金项目:重庆市卫生计生委中医药科技项目（YZ201702061） |
|
| Hits: 777 |
| Download times: 434 |
| 中文摘要: |
| 摘要 目的：探讨加味八珍汤联合mFOLFOX6方案对晚期结直肠癌患者肿瘤标志物、免疫功能和外周血磷脂酰肌醇3酶（PI3K）-丝苏氨酸蛋白激酶（Akt）信号通路的影响。方法：根据随机数字表法将广州中医药大学附属北碚中医院2020年9月至2022年1月期间收治的晚期结直肠癌患者96例分为对照组（48例，mFOLFOX6方案治疗）和研究组（48例，加味八珍汤联合mFOLFOX6方案治疗）。对比两组疗效、中医证候积分、卡式评分（KPS）、肿瘤标志物、免疫功能和外周血PI3K-Akt信号通路相关指标。结果：与对照组相比，研究组的临床总有效率升高（P<0.05）。研究组治疗后的中医证候总积分低于对照组，KPS评分高于对照组（P<0.05）。研究组治疗后的CD4+、CD4+/CD8+、免疫球蛋白（Ig）M、IgA高于对照组，CD8+低于对照组（P<0.05）。研究组治疗后的血清癌胚抗原（CEA）、糖类抗原199（CA199）、糖类抗原72-4（CA72-4）低于对照组（P<0.05）。研究组治疗后的外周血PI3K、Akt mRNA表达水平低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：加味八珍汤联合mFOLFOX6方案治疗晚期结直肠癌的疗效显著，可有效阻止晚期结直肠癌的疾病进展，增强免疫力，降低血清肿瘤标志物水平，其疗效机制可能与调节外周血PI3K-Akt信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Jiawei Bazhen decoction combined with mFOLFOX6 regimen on tumor markers, immune function and peripheral blood phosphatidylinositol3-ki-nase (PI3K) - serine protein kinase (Akt) signal pathway in patients with advanced colorectal cancer. Methods: According to the random number table method, 96 patients with advanced colorectal cancer who were treated in Beibei Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine from September 2020 to January 2022 were divided into control group (48 cases, treated with mFOLFOX6 regimen) and study group (48 cases, treated with Jiawei Bazhen decoction combined with mFOLFOX6 regimen). The efficacy, TCM syndrome score, Karnofsky score (KPS), tumor markers, immune function and peripheral blood PI3K-Akt signal pathway related indexes were compared between the two groups. Results: Compared with the control group, the total clinical effective rate in the study group was higher (P<0.05). After treatment, The total of TCM syndrome score in the study group after treatment was lower than that in the control group, and the KPS score was higher than that in the control group (P<0.05). After treatment, CD4+, CD4+/CD8+, immunoglobulin (Ig)M and IgA in the study group were higher than those in the control group, and CD8+ was lower than that in the control group (P<0.05). After treatment, the serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 72-4 (CA72-4) in the study group were lower than those in the control group (P<0.05). After treatment, the expression levels of PI3K, Akt mRNA in the peripheral blood of study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Jiawei Bazhen decoction combined with mFOLFOX6 regimen has a significant effect in the treatment of advanced colorectal cancer, which can effectively prevent the disease progression of advanced colorectal cancer, enhance immunity, and reduce the level of serum tumor markers. Its therapeutic mechanism may be related to the regulation of peripheral blood PI3K-Akt signal pathway. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
